Literature DB >> 20048223

Brain serotonin and dopamine transporter bindings in adults with high-functioning autism.

Kazuhiko Nakamura1, Yoshimoto Sekine, Yasuomi Ouchi, Masatsugu Tsujii, Etsuji Yoshikawa, Masami Futatsubashi, Kenji J Tsuchiya, Genichi Sugihara, Yasuhide Iwata, Katsuaki Suzuki, Hideo Matsuzaki, Shiro Suda, Toshiro Sugiyama, Nori Takei, Norio Mori.   

Abstract

CONTEXT: Autism is a neurodevelopmental disorder that is characterized by repetitive and/or obsessive interests and behavior and by deficits in sociability and communication. Although its neurobiological underpinnings are postulated to lie in abnormalities of the serotoninergic and dopaminergic systems, the details remain unknown.
OBJECTIVE: To determine the occurrence of changes in the binding of serotonin and dopamine transporters, which are highly selective markers for their respective neuronal systems.
DESIGN: Using positron emission tomography, we measured the binding of brain serotonin and dopamine transporters in each individual with the radioligands carbon 11 ((11)C)-labeled trans-1,2,3,5,6,10-beta-hexahydro-6-[4-(methylthio)phenyl]pyrrolo-[2,1-a]isoquinoline ([(11)C](+)McN-5652) and 2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane ([(11)C]WIN-35,428), respectively. Statistical parametric mapping was used for between-subject analysis and within-subject correlation analysis with respect to clinical variables.
SETTING: Participants recruited from the community. PARTICIPANTS: Twenty men (age range, 18-26 years; mean [SD] IQ, 99.3 [18.1]) with autism and 20 age- and IQ-matched control subjects.
RESULTS: Serotonin transporter binding was significantly lower throughout the brain in autistic individuals compared with controls (P < .05, corrected). Specifically, the reduction in the anterior and posterior cingulate cortices was associated with the impairment of social cognition in the autistic subjects (P < .05, corrected). A significant correlation was also found between repetitive and/or obsessive behavior and interests and the reduction of serotonin transporter binding in the thalamus (P < .05, corrected). In contrast, the dopamine transporter binding was significantly higher in the orbitofrontal cortex of the autistic group (P < .05, corrected in voxelwise analysis). In the orbitofrontal cortex, the dopamine transporter binding was significantly inversely correlated with serotonin transporter binding (r = -0.61; P = .004).
CONCLUSIONS: The brains of autistic individuals have abnormalities in both serotonin transporter and dopamine transporter binding. The present findings indicate that the gross abnormalities in these neurotransmitter systems may underpin the neurophysiologic mechanism of autism. Our sample was not characteristic or representative of a typical sample of adults with autism in the community.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20048223     DOI: 10.1001/archgenpsychiatry.2009.137

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  117 in total

1.  The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB.

Authors:  Ragy R Girgis; Mark Slifstein; Xiaoyan Xu; W Gordon Frankle; Evdokia Anagnostou; Stacey Wasserman; Lauren Pepa; Alexander Kolevzon; Anissa Abi-Dargham; Marc Laruelle; Eric Hollander
Journal:  Psychiatry Res       Date:  2011-11-12       Impact factor: 3.222

Review 2.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

3.  Psychiatric comorbidities in asperger syndrome and high functioning autism: diagnostic challenges.

Authors:  Luigi Mazzone; Liliana Ruta; Laura Reale
Journal:  Ann Gen Psychiatry       Date:  2012-06-25       Impact factor: 3.455

4.  Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems.

Authors:  Elizabeth Hammock; Jeremy Veenstra-VanderWeele; Zhongyu Yan; Travis M Kerr; Marianna Morris; George M Anderson; C Sue Carter; Edwin H Cook; Suma Jacob
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-05-26       Impact factor: 8.829

5.  Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior.

Authors:  Georgianna G Gould; Julie G Hensler; Teresa F Burke; Robert H Benno; Emmanuel S Onaivi; Lynette C Daws
Journal:  J Neurochem       Date:  2010-12-02       Impact factor: 5.372

Review 6.  Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.

Authors:  Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

7.  Sleep in Autism Spectrum Disorders.

Authors:  Olivia J Veatch; Angela C Maxwell-Horn; Beth A Malow
Journal:  Curr Sleep Med Rep       Date:  2015-06

8.  Pathophysiological distortions in time perception and timed performance.

Authors:  Melissa J Allman; Warren H Meck
Journal:  Brain       Date:  2011-09-15       Impact factor: 13.501

9.  Protocadherin α (PCDHA) as a novel susceptibility gene for autism.

Authors:  Ayyappan Anitha; Ismail Thanseem; Kazuhiko Nakamura; Kazuo Yamada; Yoshimi Iwayama; Tomoko Toyota; Yasuhide Iwata; Katsuaki Suzuki; Toshiro Sugiyama; Masatsugu Tsujii; Takeo Yoshikawa; Norio Mori
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

Review 10.  The serotonin system in autism spectrum disorder: From biomarker to animal models.

Authors:  C L Muller; A M J Anacker; J Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.